Back to top
more

Myomo (MYO)

(Delayed Data from AMEX)

$1.53 USD

1.53
373,225

+0.05 (3.38%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $1.55 +0.02 (1.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (100 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.50% and 43.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -29.38% and 29.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -7.37% and 8.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myomo, Inc. (MYO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Myomo, Inc. (MYO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ResMed (RMD) Rides on New Product Portfolio, SaaS Growth

by Zacks Equity Research

Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.

Zacks Equity Research

Here's Why You Should Add ResMed (RMD) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.

Zacks Equity Research

QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe

by Zacks Equity Research

QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.

Zacks Equity Research

ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.

Zacks Equity Research

Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark

by Zacks Equity Research

Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.

Zacks Equity Research

Align (ALGN) Rides on Volume Expansion Despite Cost Concerns

by Zacks Equity Research

We are upbeat about Align's (ALGN) consistent uptrend in Invisalign volumes across all geographies.